Abstract
BackgroundThe complete response rate of cervical high-grade squamous intraepithelial lesion (cHSIL) patients to imiquimod immunotherapy is approximately 60%. Consequently, many patients are exposed to unnecessary adverse effects of imiquimod. On...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have